Capricor Therapeutics Faces Class Action Suit Following FDA Data Critique

The lawsuit, Nkamga v. Capricor Therapeutics, Inc., claims that top executives at the biotechnology firm violated the Securities Exchange Act of 1934 by failing to disclose critical deviations from the pre-specified statistical analysis plan for Deramiocel, a therapy targeting Duchenne muscular dystrophy. According to the complaint, Capricor modified its analytical methods without prior FDA agreement, creating a significant risk that the agency would deem the clinical results insufficient to prove effectiveness.

Regulatory scrutiny intensified on July 27, 2026, when the FDA released briefing documents for an upcoming advisory committee meeting. The agency noted that the final version of the statistical analysis plan was created shortly before data unblinding and was never submitted for review, labeling the company's subsequent analyses as exploratory. Following the release of these documents and an investor note from Cantor Fitzgerald describing the findings as damaging to the integrity of the data, Capricor’s stock price plummeted 64%. A further 36% decline followed on July 30, after an advisory panel voted 9-3 that available evidence failed to support the drug's efficacy for treating DMD-associated cardiomyopathy. Robbins Geller Rudman & Dowd LLP is representing the plaintiffs in the case.